RUNX1 and metabolic dysfunction-associated steatotic liver disease: First, we did not observe significant differences in the RUNX1 hepatic expression between patients with NAFLD and those with NL histology (Figure 2A); however, when we analyzed the hepatic relative mRNA abundance of RUNX1 according to different degrees of NAFLD, we found that the RUNX1 hepatic expression was significantly higher in patients with SS than those with NL or NASH.